^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + iparomlimab/tuvonralimab (PSB205) (PD1 inhibitor, CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
332P - A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR mutant cohort
Published date:
11/28/2022
Excerpt:
...we report the efficacy and safety results from the EGFR mutant cohort of an ongoing Ph II study of QL1706+chemotherapy (chemo)+bevacizumab in patients (pts) with advanced NSCLC…the ORR was 64.5% (20/31) and DCR was 93.5% (29/31)....The 6-month PFS rate was 61.3%. The median follow-up for OS was 5.75 months (IQR: 4.86, 7.10)....QL1706+platinum-based chemo+bevacizumab demonstrated promising clinical activity, with favorable tolerability in pts with EGFR mutant NSCLC and failed in EGFR TKI therapy.
Secondary therapy:
Chemotherapy
Trial ID:
